The Relationship of MMP-9 Gene Polymorphism rs3918242 (C-1562T) with Clinical-Pathological Features in Luminal Subtype Breast Cancer

Background: Breast cancer is a malignant tumor arising from the ductal or lobular epithelium. The Matrix Metalloproteinase-9 (MMP-9) rs3918242 polymorphism has been reported as a genetic factor influencing cancer cell proliferation and tumor progression. Therefore, this study aims to investigate the association between the MMP-9 rs3918242 (C-1562T) gene polymorphism and the clinicopathology of luminal subtype breast cancer.

Methods: This study is a descriptive-analytic research with a cross-sectional design. The polymerase chain reaction (PCR) method was used to detect the MMP-9 rs3918242 (C-1562T) gene polymorphism in patients’ blood samples. Data were analyzed using SPSS version 26.0.

Results: The mean age of the participants, age at diagnosis, and age at menarche were 55.67±10.64, 53.29±10.28, and 13.48±1.60 years, respectively. Most participants had fewer than 2 childbirths (54.8%), and the majority were postmenopausal (64.5%). Regarding tumor characteristics, most cases were early-stage breast cancer (19 patients, 61.3%), while histological grading showed a predominance of high-grade tumors (23 patients, 74.2%). Bivariate analysis revealed a significant association between the MMP-9 rs3918242 (C-1562T) gene polymorphism and the clinicopathological features of luminal subtype breast cancer, including stage and metastasis.

Conclusion: A significant association was identified between the MMP-9 rs3918242 gene polymorphism and the clinicopathological characteristics of patients with luminal subtype breast cancer.

1. Brufsky A, Miles D, Zvirbule Z, Eniu A, Lopez-Miranda E, Seo J, et al. Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I. Cancer Research. American Association for Cancer Research. 2018;78(4Supplement):P5-21-01.

2. Papaoiconomou E, Lymperi M, Petraki C, et al. Kiss-1/ GPR54 protein expression in breast cancer. Anticancer Res. 2014;34(3):1401-1407. PMID: 24596387

3. Feng Y, Spezia M, Huang S, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77-106. PMID: 30258937. PMCID: PMC6147049. https://doi.org/10.1016/j.gendis.2018.05.001

4. Jana S, Madhu Krishna B, Singhal J, et al. SOX9: The master regulator of cell fate in breast cancer. Biochem Pharmacol. 2020;174:113789. PMID: 31911091. PMCID: PMC9048250. https://doi.org/10.1016/j.bcp.2019.113789

5. Sasmana I, Putri P, Dewi N, Supadmanaba I, Wihandani D. Current Development of Virotherapy in Breast Cancer: A Brief Review. Acta Medica Bulg. 2024;51(4):86–94. https://doi.org/10.2478/AMB-2024-0084

6. International Agency for Research on Cancer (IARC). Indonesia – Global Cancer Observatory. Globocan. 2020;858:1–2.

7. Society AC. Breast Cancer Fact and Figures 2017-2018. 2018. Available by: https://www.cancer.org/research/cancer-factsstatistics/breast-cancer-facts-figures.html

8. Li ZH, Hu PH, Tu JH, Yu NS. Luminal B breast cancer: patterns of recurrence and clinical outcome. Oncotarget. 2016;7(40):6502465033. PMID: 27542253. PMCID: PMC5323135. https://doi.org/10.18632/oncotarget.11344

9. Kabel AM. Tumor markers of breast cancer: New prospectives. J Oncol Sci. 2017;3(1):5–11. https://doi.org/10.1016/j.jons.2017.01.001

10. Sasmana IGAP, Wiranata S, Yogananda KC, Wihandani DM, Supadmanaba IGP. Clinicopathological and Prognostic Significance of SRY-Box Transcription Factor 2 (SOX2) Overexpression in Central Nervous System Tumor : A Meta-Analysis. Bali Med J. 2023;12(2):1733–9. https://doi.org/10.15562/bmj.v12i2.4493

11. Jafari R, Majidi Zolbanin N, Majidi J, et al. Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells. Iran Biomed J. 2019;23(1):21-33. PMID: 30041514. PMCID: PMC6305820. https://doi.org/10.29252/.23.1.21

12. Platonov ME, Borovjagin AV, Kaverina N, et al. KISS1 tumor suppressor restricts angiogenesis of breast cancer brain metastases and sensitizes them to oncolytic virotherapy in vitro. Cancer Lett. 2018;417:75-88. PMID: 29269086. https://doi.org/10.1016/j.canlet.2017.12.024

13. Lin BW, Gong CC, Song HF, Cui YY. Effects of anthocyanins on the prevention and treatment of cancer. Br J Pharmacol. 2017;174(11):1226-1243. PMID: 27646173. PMCID: PMC5429338. https://doi.org/10.1111/bph.13627

14. Huang H. Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances. Sensors (Basel). 2018;18(10):3249. PMID: 30262739. PMCID: PMC6211011. https://doi.org/10.3390/s18103249

15. Rahimi Z, Yari K, Rahimi Z. Matrix metalloproteinase-9 -1562T allele and its combination with MMP-2 -735 C allele are risk factors for breast cancer. Asian Pac J Cancer Prev. 2015;16(3):1175-1179. PMID: 25735351. https://doi.org/10.7314/apjcp.2015.16.3.1175

16. Xu T, Zhang S, Qiu D, Li X, Fan Y. Association between matrix metalloproteinase 9 polymorphisms and breast cancer risk: An updated meta-analysis and trial sequential analysis. Gene. 2020;759:144972. PMID: 32739585. https://doi.org/10.1016/j.gene.2020.144972

17. Caykara B, Alsaadoni H, Pençe S, Pençe HH, Ötünçtemur A. Investigation of MMP-9 rs3918242 and TIMP2 rs8179090 polymorphisms in renal cell carcinoma tissues. Turkish J Biochem. 2020;45(4):429–34.

18. Sutadarma IWG, Supadmanaba IGP, Adiputra PAT, Devy AAT, Indrakusuma AABP, Sasmana IGAP. Relationship Between XRCC1 Arg399gln Polymorphism and Risk of Luminal Subtype Breast Cancer in Bali, Indonesia. Acta Medica (Hradec Kralove). 2025;68(1):21-25. PMID: 40521603. https://doi.org/10.14712/18059694.2025.14

19. Felizi RT, Veiga MG, Carelli Filho I, Souto RPD, Fernandes CE, Oliveira E. Association between Matrix Metallopeptidase 9 Polymorphism and Breast Cancer Risk. Associação entre o polimorfismo do gene metalopeptidase de matriz 9 e o risco de câncer de mama. Rev Bras Ginecol Obstet. 2018;40(10):620624. PMID: 30352460. PMCID: PMC10316932. https://doi.org/10.1055/s-0038-1673366

20. Subiyanto D, Kadi TA, Ismaiyah I, Abdurrahman N, Utomo YP, Alifiansyah AR, et al. Subtipe Molekuler Kanker Payudara di RSUD Madiun dan Hubungannya dengan Grading Histopatologi. Media Penelitian dan Pengembangan Kesehatan. 2021;31(3):193– 202. https://doi.org/10.22435/mpk.v31i3.4986

21. Abd Elmaogoud Ragab Ibrahim F, Essam Elfeky S, Haroun M, et al. Association of matrix metalloproteinases 3 and 9 single nucleotide polymorphisms with breast cancer risk: A case-control study. Mol Clin Oncol. 2020;13(1):54-62. PMID: 32454974. PMCID: PMC7241239. https://doi.org/10.3892/mco.2020.2041

22. Kimi L, Ghatak S, Yadav RP, et al. Relevance of GSTM1, GSTT1 and GSTP1 Gene Polymorphism to Breast Cancer Susceptibility in Mizoram Population, Northeast India. Biochem Genet. 2016;54(1):41-49. PMID: 26407578. https://doi.org/10.1007/s10528-015-9698-5

23. Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34-74. PMID: 24269963. https://doi.org/10.1016/j.phrs.2013.11.002

24. Hong S, Li J, Wang S. 18FDG PET-CT for diagnosis of distant metastases in breast cancer patients. A meta-analysis. Surg Oncol. 2013;22(2):139-143. PMID: 23566435. https://doi.org/10.1016/j.suronc.2013.03.001

25. Szecsi PB, Larsen J, Hørby J, Axelsson CK. Seroma production after breast cancer surgery has a pro-inflammatory component. Open Breast Cancer J. 2012;4:11–7. https://doi.org/10.2174/1876817201204010011

26. O Bryan SM, Mathis JM. Oncolytic Virotherapy for Breast Cancer Treatment. Curr Gene Ther. 2018;18(4):192-205. PMID: 30207220. PMCID: PMC7499349. https://doi.org/10.2174/1566523218666180910163805

27. Zahra Dehghan Manshadi, Mohammad Hamid FK, Heidar Tayebinia IK. Metalloproteinase Gene Polymorphisms Metastasis in Women with Breast Cancer in Central Iran. 2018;9:123–31.